Skip to content
Coming soon
  • Agriculture Tech
  • AI Agents & Models
  • Autonomy
  • Avatars & Digital Humans
  • Biotech / Synthetic Biology
  • Blockchain / Crypto
  • Brain-Computer Interfaces
  • Climate Tech
  • Cloud & Edge Computing
  • Commerce
  • Cybersecurity
  • Data Infrastructure
  • Defense
  • Digital Identity
  • Education Tech
  • Energy
  • Fashion & Textiles
  • Food Tech
  • Healthcare Systems
  • Longevity & Human Enhancement
  • Manufacturing
  • Materials Science
  • Mobility
  • Quantum Computing
  • Smart Homes
  • Space Tech
  • Voice & Conversational Interfaces
  • Wearables
Creative Tools
Creative Tools subject logo

Adobe's Firefly Assistant delivers conversational prompting, underwhelming execution

[[c:859651b5-e9f3-451f-8503-c695d6182870|Adobe]] has shipped a conversational AI agent for Creative Cloud that lets users describe what they want instead of manually editing—but [[r:1|early reviews]] suggest the output quality lags behind what practitioners achieve with direct tool control.

DevTools
DevTools subject logo

Anthropic closes $65B Series H at $900B valuation, ships Opus 4.8 and Dynamic Workflows

The Claude maker raises what would be the largest venture round in history and pairs it with a model update and agent-orchestration layer designed to hold enterprise workloads as OpenAI's lead narrows.

Health Tech
Health Tech subject logo

FDA opens wellness wearables floodgates; Oura accelerates blood pressure, glucose roadmap

The FDA just cleared continuous blood pressure and glucose monitoring to launch as "wellness" products—no premarket review required—and [[c:9b09d6b5-4be1-4a6a-b37e-d0b03a0f09ff|Oura Health]] is racing to ship both features ahead of its IPO.

Payments
Payments subject logo

Visa invests in Replit to arm its engineers with agentic tooling as payment networks face software-velocity pressure

The card network backs the same AI-native development platform already used by over 1,000 of its own engineers, signaling that payment infrastructure incumbents now compete on software-build speed—not just settlement scale.

Robotics
Robotics subject logo

Figure hits production scale, exits demo phase with manufacturing ramp

The AI-first humanoid company moves from controlled BMW pilots and endurance videos to volume manufacturing—a signal that commercial deployment timelines are compressing across the sector.

Founded
1982
44 years
Status
Public
ADBE
Market cap
$105.9B
Headcount
10k+

The story

We're tracking this as a product-delivery moment rather than a strategic pivot. Adobe launched Firefly AI Assistant[1] with conversational control across Photoshop, Illustrator, and Premiere Pro—users type or speak commands, and the model attempts to apply edits, generate assets, or adjust parameters. The interface promise is seamless: natural language replaces menu diving. The execution challenge is aesthetic: reviewers report that outputs frequently miss the mark on subtlety, composition, and professional polish, requiring manual correction that negates the time saved by the prompt. This isn't a model-capability surprise. Adobe's Firefly backbone was trained on Adobe Stock and permissioned content, prioritizing legal defensibility over stylistic range. That trade-off insulated the company from copyright litigation but constrained the aesthetic ceiling. Meanwhile, Midjourney and OpenAI's DALL-E trained on broader datasets and consistently deliver more refined outputs—but neither offers the same tight integration into a professional workflow suite. Adobe's moat was always the workflow lock-in: Creative Cloud subscriptions bundle tools, fonts, libraries, and collaboration features that make switching painful. Firefly Assistant extends that bundle with AI convenience, but the "mediocre intern" label signals that convenience alone won't defend margin if the quality gap persists. The strategic question is whether conversational UX becomes a wedge for standalone challengers. If prompting replaces manual skill as the primary interface, then Adobe's decades of tool sophistication matter less—users will pick the model that delivers the best output, not the deepest feature set. Figma already demonstrated that web-native, collaboration-first design tools can peel away Adobe's Illustrator user base. A future where Midjourney or Runway adds lightweight editing layers around their superior generation engines would compress Adobe's creative-suite pricing power. For now, professional designers still need Photoshop's layer control and Premiere's timeline precision—but that dependency shrinks every time a model gets good enough to handle the last-mile polish conversationally.

Continue reading

The rest of this story is for subscribers.

Including Our Take, the Tailwinds & headwinds framing, Connections across the FOBI roster, and What should you do.

Founding
50% off
$5
/month
 
91 of 100 spots left
Full
$10
/month
 
Available once all 100 Founding Member spots are claimed.
Get full access

Already subscribed? Sign in →

Founded
2021
5 years
Status
Private
Total raised
$56.4B
Headcount
1k-5k

The story

Anthropic closed a $65 billion Series H[1] at a $900 billion pre-money valuation, lifting total funding to more than $56 billion and cementing the largest venture round on record. The raise coincides with two product releases: Opus 4.8—a foundation-model refresh with gains in reasoning and code generation—and Dynamic Workflows, an orchestration layer for Claude Code that allows developers to compose multi-step agent routines without leaving the terminal. The pairing is deliberate: the capital buys compute at a scale that keeps Anthropic within reach of OpenAI's training runs, while the product releases convert that inference budget into stickier enterprise workloads that go beyond single-shot completions. Dynamic Workflows matters more than the headline benchmark deltas. It exposes a DAG-based interface inside Claude Code, letting users define conditional branches, retry logic, and multi-agent coordination—essentially moving orchestration primitives that previously lived in LangChain or custom glue code into the core product. Early access users report that workflows targeting AWS HashiCorp Terraform stacks or GitHub Actions pipelines now run end-to-end without fallback to human triage. The shift turns Claude Code from a completion engine into a durable runtime for agent-shaped work, which is where the gross-dollar-value seats live. OpenAI's Codex CLI still leads in raw adoption, but it lacks a first-party orchestration story; most production deployments bolt on Temporal or custom state machines, fragmenting the developer experience. The $900 billion pre-money valuation reflects a bet that the frontier-model oligopoly compresses to two or three players and that capital intensity is now the primary barrier. Anthropic has burned an estimated $18–22 billion over the trailing twelve months on compute, data, and forward-deployed engineering headcount. The new round buys eighteen to twenty-four months of runway at current burn, which means the next financing or liquidity event likely lands in late 2027 or early 2028—right when the first wave of multi-year enterprise Claude Code contracts comes up for renewal. The raise also pre-empts OpenAI's rumored Series G at a similar scale, ensuring neither player can use a capital advantage to force the other into a down-round or strategic sale.

Continue reading

The rest of this story is for subscribers.

Including Our Take, the Tailwinds & headwinds framing, Connections across the FOBI roster, and What should you do.

Founding
50% off
$5
/month
 
91 of 100 spots left
Full
$10
/month
 
Available once all 100 Founding Member spots are claimed.
Get full access

Already subscribed? Sign in →

Founded
2013
13 years
Status
Private
Total raised
$1.2B
Headcount
1k-5k

The story

The FDA's updated wellness guidance[1], published this week, permits continuous blood pressure and glucose sensors to reach consumers without premarket authorization provided they're labeled for "general wellness" rather than diagnostic use. The shift eliminates a regulatory barrier that had kept consumer wearables out of cardiovascular and metabolic monitoring—domains historically reserved for devices cleared as medical instruments. Oura Health, which confidentially filed for IPO three weeks ago, responded within 48 hours, announcing it will add cuffless blood pressure monitoring to its Ring 5 hardware by Q4 2026 and continuous glucose tracking in 2027. The features leverage optical sensors already embedded in the ring's third-generation LED array, combined with proprietary pulse-wave algorithms and a subscription analytics tier priced at $5.99 per month on top of Oura's existing $6.99 membership. The timing is deliberate: Oura's S-1 filing framed the company's growth thesis around "expanding from sleep and readiness into broader cardiovascular and metabolic health," and the FDA's guidance removed the single largest execution risk to that narrative. The guidance rewrites the competitive map for wearables at scale. Abbott's FreeStyle Libre, the world's most widely adopted continuous glucose monitor, built a multi-billion-dollar franchise behind clinical accuracy claims and payor reimbursement. That moat just narrowed sharply: consumer hardware companies can now offer trend-based glucose data without navigating Abbott's regulatory playbook or waiting for insurance coverage. The same logic applies to blood pressure. Traditional cuff-based monitors and the handful of cuffless devices that pursued FDA clearance—Omron, Aktiia—spent years in clinical validation. Wellness-labeled devices bypass that gauntlet entirely, trading diagnostic precision for speed to market. The FDA's explicit framing—"these products provide users with health information but are not intended to diagnose, treat, cure, or prevent disease"—creates a liability shield for manufacturers and shifts risk assessment to consumers, who must now distinguish wellness trend data from clinically actionable measurements. The second-order effect is capital reallocation toward consumer wellness platforms that can layer these sensors into existing engagement loops. Oura's model is instructive: the company already captures nocturnal physiology (HRV, temperature, SpO2) and uses illness-detection algorithms to flag cardiovascular and respiratory anomalies. Adding blood pressure and glucose extends the data surface without requiring new hardware form factors, and the subscription model converts sensor data into recurring revenue independent of device refresh cycles. We're tracking whether Oura can ship accurate-enough pulse-wave BP algorithms—optical sensors measure pulse transit time as a proxy for arterial stiffness, but accuracy degrades with wrist movement, skin tone variation, and calibration drift—and whether the "wellness" liability framing holds when consumers use trend data to make medication or diet decisions. The FDA punted downstream risk to platforms, and the first adverse event tied to a wellness sensor will test whether the regulatory perimeter can hold.

Continue reading

The rest of this story is for subscribers.

Including Our Take, the Tailwinds & headwinds framing, Connections across the FOBI roster, and What should you do.

Founding
50% off
$5
/month
 
91 of 100 spots left
Full
$10
/month
 
Available once all 100 Founding Member spots are claimed.
Get full access

Already subscribed? Sign in →

Founded
1958
68 years
Status
Public
V
Market cap
$614.9B
Headcount
10k+

The story

Visa invested in Replit[1], the agentic software creation platform, on the same day the company disclosed that over 1,000 of its engineers already use the tool internally. The investment amount wasn't disclosed, but the signal is clear: payment infrastructure incumbents are now competing on software-build velocity, not just settlement scale or network reach. Replit's platform uses AI agents to accelerate code generation, environment setup, and deployment—effectively turning every engineer into a 10× builder. For Visa, this isn't a venture bet on an emerging category; it's paying to entrench a tool that's already core to how it ships software. The timing connects directly to Visa's broader agentic-commerce buildout. Over the past month we've tracked Visa publishing merchant checklists for agent-ready product catalogs, trust frameworks for autonomous payment delegation, and issuer research showing that only 17% of card issuers maintain high lifetime value as money-flow embedding separates winners from commodity pipes. Every one of those initiatives demands software—merchant APIs, issuer dashboards, fraud-monitoring tools, token-authentication flows, agent-identity verification layers. The bottleneck isn't capital or regulatory clarity; it's engineering throughput. Stripe spent the last decade training the market to expect weekly API updates and same-day integration docs. Worldpay and the card networks can't afford multi-quarter release cycles when merchants are restructuring checkout flows for agent buyers in real time. The deeper read: Visa is internalizing the same agentic-tooling thesis it's been selling to merchants and issuers. If agents will reshape commerce by acting autonomously, then the infrastructure layer—authentication, fraud scoring, settlement orchestration—must be rebuilt with agent-scale modularity and agent-speed iteration. That demands a different engineering culture, one where a product manager can prototype a new fraud heuristic or issuer API in hours, not sprints. Replit is the wedge. The stock closed down 0.81% on the day—the market priced this as a feature release, not a strategic repositioning. We read it the opposite way: the network that can out-ship its competitors on software will determine which agentic-commerce architectures become standard, and that determines where transaction flow—and fee capture—accrues over the next five years.

Continue reading

The rest of this story is for subscribers.

Including Our Take, the Tailwinds & headwinds framing, Connections across the FOBI roster, and What should you do.

Founding
50% off
$5
/month
 
91 of 100 spots left
Full
$10
/month
 
Available once all 100 Founding Member spots are claimed.
Get full access

Already subscribed? Sign in →

Founded
2022
4 years
Status
Private
Total raised
$1.7B
Headcount
201-500

The story

Figure has moved from demonstrating what its humanoid can do to manufacturing it at volume. The company announced it is ramping production[1] to levels that support commercial deployment—no longer building units one at a time for controlled BMW plant trials or 60-minute endurance showcases, but scaling the assembly line to meet order books. This is the inflection point every robotics company chases: the moment when engineering risk converts to execution risk, when the question shifts from "does it work?" to "can you ship?" The timing is strategic. Figure spent the last year de-risking the product—BMW integration, natural walking gaits, multi-hour task endurance, package sorting under real logistics conditions—and then secured over $1B in September 2025 explicitly to fund this ramp. That capital bought manufacturing capacity, supply-chain lock-in for high-tolerance actuators, and the Brookfield real-estate partnership to generate training data at scale. The company is now converting that infrastructure into throughput. Meanwhile, Tesla Optimus remains in internal pilot mode and UBTECH's Walker S has yet to demonstrate the same task generalization or deployment velocity. Figure's manufacturing announcement is a bid to own first-mover commercial scale in AI-native humanoids before incumbents or better-capitalized challengers close the gap. What this really signals: the humanoid sector is exiting the demo-and-fundraise cycle and entering a manufacturing and unit-economics race. The companies that can build robots faster and cheaper than the labor they displace will capture the trillions in addressable warehouse, logistics, and light-manufacturing TAM. Figure's ramp is the first public evidence that an AI-first player believes it has line-of-sight to those economics at production scale. If the ramp holds, the company will define the commercial playbook for the sector; if it stumbles on yield, lead times, or field reliability, it hands Tesla Optimus and the incumbent automation providers—ABB, FANUC, Symbotic—time to catch up or leapfrog with their own humanoid or task-specific automation at better cost.

Continue reading

The rest of this story is for subscribers.

Including Our Take, the Tailwinds & headwinds framing, Connections across the FOBI roster, and What should you do.

Founding
50% off
$5
/month
 
91 of 100 spots left
Full
$10
/month
 
Available once all 100 Founding Member spots are claimed.
Get full access

Already subscribed? Sign in →